D. E. Shaw & Co. Inc. lowered its stake in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 55.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,543 shares of the company's stock after selling 51,734 shares during the quarter. D. E. Shaw & Co. Inc.'s holdings in HUTCHMED were worth $599,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in the business. XY Capital Ltd bought a new stake in shares of HUTCHMED in the 4th quarter worth $673,000. ABC Arbitrage SA purchased a new stake in shares of HUTCHMED during the fourth quarter valued at $500,000. Jane Street Group LLC lifted its holdings in shares of HUTCHMED by 54.7% during the fourth quarter. Jane Street Group LLC now owns 97,470 shares of the company's stock valued at $1,405,000 after purchasing an additional 34,473 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of HUTCHMED by 18.4% during the fourth quarter. Renaissance Technologies LLC now owns 188,539 shares of the company's stock valued at $2,717,000 after purchasing an additional 29,239 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of HUTCHMED during the fourth quarter valued at $261,000. Institutional investors and hedge funds own 8.82% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have recently commented on HCM. HSBC downgraded HUTCHMED from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. Wall Street Zen downgraded HUTCHMED from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd.
Get Our Latest Analysis on HUTCHMED
HUTCHMED Price Performance
NASDAQ:HCM traded up $0.63 during trading hours on Thursday, hitting $13.86. 41,144 shares of the company's stock traded hands, compared to its average volume of 100,373. HUTCHMED has a twelve month low of $11.51 and a twelve month high of $21.50. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. The stock's fifty day moving average price is $14.12 and its two-hundred day moving average price is $14.92.
About HUTCHMED
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Further Reading
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
